Evidence map›Paper›PMID 29116202›Full record

ArticleNature communications2017

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.

Fátima Valdés-Mora, Cathryn M Gould, Yolanda Colino-Sanguino, Wenjia Qu, Jenny Z Song, Kylie M Taylor, Fabian A Buske, Aaron L Statham, Shalima S Nair, Nicola J Armstrong and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Epigenomic insights into common human disease pathology.Cellular and molecular life sciences : CMLS · 2024
    Review
  13. Review
  14. Review
  15. Article
  16. PGEProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  17. Epigenetic (De)regulation in Prostate Cancer.Cancer treatment and research · 2023
    Article
  18. Review
  19. Review
  20. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Fátima Valdés-MoraHistone Variants Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia. f.valdesmora@garvan.org.au.ORCID http://orcid.org/0000-0001-7490-0114
Cathryn M GouldHistone Variants Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Yolanda Colino-SanguinoHistone Variants Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Wenjia QuEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Jenny Z SongEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Kylie M TaylorHistone Variants Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Fabian A BuskeEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Aaron L StathamEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Shalima S NairEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Nicola J ArmstrongMathematics and Statistics, Murdoch University, Perth, WA, 6150, Australia.
James G KenchDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.
Kenneth M L LeeSydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
Lisa G HorvathSydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
Minru QiuDepartment of Anatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, NSW, 2010, Australia.
Alexei IlinykhHistone Variants Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Nicole S Yeo-TehHistone Variants Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
David Gallego-OrtegaSt. Vincent's Clinical School, UNSW Sydney, Sydney, NSW, 2010, Australia.ORCID http://orcid.org/0000-0002-2347-7835
Clare StirzakerEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Susan J ClarkEpigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia. s.clark@garvan.org.au.
Garvan Institute of Medical Research · AUThe University of Sydney · AUMurdoch University · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acetylation of the histone variant H2A.Z (H2A.Zac) occurs at active promoters and is associated with oncogene activation in prostate cancer, but its role in enhancer function is still poorly understood. Here we show that H2A.Zac containing nucleosomes are commonly redistributed to neo-enhancers in cancer resulting in a concomitant gain of chromatin accessibility and ectopic gene expression. Notably incorporation of acetylated H2A.Z nucleosomes is a pre-requisite for activation of Androgen receptor (AR) associated enhancers. H2A.Zac nucleosome occupancy is rapidly remodeled to flank the AR sites to initiate the formation of nucleosome-free regions and the production of AR-enhancer RNAs upon androgen treatment. Remarkably higher levels of global H2A.Zac correlate with poorer prognosis. Altogether these data demonstrate the novel contribution of H2A.Zac in activation of newly formed enhancers in prostate cancer.

Indexed as

AcetylationChromatinDisease-Free SurvivalEnhancer Elements, GeneticEpigenesis, GeneticGene Expression Regulation, NeoplasticHistonesHumansMaleNucleosomesProstatic NeoplasmsReceptors, AndrogenAR protein, humanChromatinhistone H2A.F-ZHistonesNucleosomesReceptors, Androgen

Identifiers

PMID29116202
PMCPMC5676741
OpenAlexW2765526808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.